20-F: Oncolytics Biotech Inc. Reports Full Year 2024 Results and Provides Corporate Update

Oncolytics Biotech Inc. announces its financial results for the year ended December 31, 2024, and provides an update on its clinical development programs and corporate activities.

Summary

• Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company focused on developing pelareorep, an immunotherapeutic agent.
• The company's primary focus is on advancing programs in HR+/HER2metastatic breast cancer and metastatic pancreatic ductal adenocarcinoma to registration-enabled clinical studies.
• Oncolytics is also exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
• The company reported a net loss of $31.71 million for the year ended December 31, 2024.
• As of December 31, 2024, Oncolytics had cash and cash equivalents of $15.94 million.
• The company estimates its cash and cash equivalents will fund operations into the third quarter of 2025 without additional funding.
• Oncolytics plans to raise additional funds through the sale of common shares or other capital resources.
• The company is seeking a CEO after the previous CEO resigned due to health concerns.
• On February 13, 2025, Oncolytics received a notification from Nasdaq that its share price was below the minimum required for continued listing.
• The company has until August 12, 2025, to regain compliance with Nasdaq listing requirements.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive clinical trial results and ongoing development programs, the company's financial situation and Nasdaq listing issues raise concerns.

Positives

• The FDA supports PFS as the primary endpoint for the registration-enabling trial in HR+/HER2mBC.
• BRACELET-1 study results showed a greater than 12-month survival advantage with PTX + pelareorep compared to PTX alone.
• The GOBLET study's anal cancer cohort showed a tripling of objective response compared to checkpoint inhibitor therapy alone.
• The company is collaborating with GCAR to evaluate pelareorep in metastatic pancreatic cancer patients, which could accelerate the registrational timeline and provide substantial cost savings.
• The company has an extensive patent portfolio covering pelareorep and related methods.

Negatives

• The company has a history of losses and expects to continue incurring substantial losses.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company is dependent on raising additional financing.
• The company's share price is below the minimum required for continued listing on Nasdaq.
• The company is economically dependent on its toll manufacturers.

Risks

• The company may not be able to secure additional financing on acceptable terms or at all.
• The company may be required to reduce or eliminate planned expenditures if additional financing is not obtained.
• Clinical trials may not be successful.
• The company may not be able to obtain regulatory approval for pelareorep.
• The company faces intense competition in the biotechnology industry.
• The company is dependent on key employees and collaborators.
• The company's operations may be adversely affected by disruptions to its information technology systems.
• The company is likely a passive foreign investment company which may have adverse U.S. federal income tax consequences for U.S. shareholders.

Future Outlook

The company plans to advance its programs in HR+/HER2metastatic breast cancer and metastatic pancreatic ductal adenocarcinoma to registration-enabled clinical studies and explore opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study. The company estimates its cash and cash equivalents will fund operations into the third quarter of 2025 without additional funding.

Industry Context

The document highlights Oncolytics' focus on developing pelareorep as an immunotherapeutic agent in the competitive oncology market, where there is a growing emphasis on combination therapies and personalized medicine. The company's collaborations and clinical trial programs reflect a broader industry trend towards exploring novel approaches to enhance immune responses and improve outcomes in cancer treatment.

Comparison to Industry Standards

• The objective response rate (ORR) of 33% in the anal carcinoma cohort of the GOBLET platform study compares favorably to the 10-24% ORRs reported in recent clinical trials of checkpoint inhibitor therapy in similar second-line or later anal carcinoma populations.
• The observed ORR of 62% in first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) patients treated with the combination of pelareorep, atezolizumab, and gemcitabine/nab-paclitaxel in the GOBLET platform study is substantially higher than the typical ORR of ~25% reported in historical trials of gemcitabine and nab-paclitaxel in metastatic pancreatic cancer.
• In a single-arm study of gemcitabine plus pelareorep, known as REO 017, first-line patients with metastatic PDAC, had a median OS of 10.2 months with 1-year and 2-year survival rates of 45% and 24%, respectively, which is encouraging when compared to an average median OS of less than 7 months, and 1-year and 2-year survival rates of approximately 22% and 6%, respectively, for metastatic PDAC patients treated with gemcitabine alone in benchmark studies.

Management Changes

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees face uncertainty due to the company's financial situation and potential cost-cutting measures.
• Patients may benefit from the continued development of pelareorep as a cancer treatment.
• Suppliers and creditors may be affected by the company's financial situation and potential changes in payment terms.

Next Steps

• Finalize submission to the FDA for a randomized phase 2 trial examining pelareorep + paclitaxel combination therapy in breast cancer and enroll the first patient.
• Continue enrolling GOBLET's expanded anal cancer and newly added pancreatic cancer cohorts.
• Announce interim efficacy data from GOBLET Cohort 5 in the second half of 2025.
• Finalize the master protocol associated with a pancreatic study with GCAR and engage the FDA to discuss the adaptive design.
• Execute a formal assessment of the drug substance production process in preparation for performance qualification.
• Execute a cGMP production run.
• Complete the potency assay validation.
• Supply distribution for ongoing and planned studies.

Key Dates